UroGen Pharma Ltd URGN
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$1.91M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 31.8% of shares outstanding.
Largest holders
By investor type
Reported short interest has held roughly steady near 10.45% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Federated Hermes, Inc. | Mutual Fund | 2026/Q3 | +304,259 | 0.6% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +171,257 | 0.4% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +144,757 | 0.5% |
| Squarepoint OPS LLC | Hedge Fund | 2026/Q3 | +105,500 | 0.2% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +88,097 | 0.4% |
| Raymond James Financial, Inc. | Public Company | 2026/Q3 | +60,148 | 0.1% |
| Robert L. Bender, Inc. | Mutual Fund | 2026/Q3 | +34,701 | 0.1% |
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +34,049 | 0.2% |
| FMR | Mutual Fund | 2026/Q3 | +33,804 | 0.5% |
| Calamos Investments LLC | Mutual Fund | 2026/Q3 | +97,953 | 0.2% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +87,557 | 0.2% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +1,525,549 | 3.1% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q3 | +1,065,939 | 2.2% |
| The Toronto-Dominion Bank | Public Company | 2026/Q3 | +753,243 | 6.9% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +395,060 | 4.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Sale | -2,202 | $36.69 | 4,561 |
| 7 Oct 2026 | Christopher Degnan | Chief Financial Officer | Derivative Exercise and Retained | +2,281 | – | 4,561 |
| 7 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Intent to Sell (Form 144) | -871 | $44.09 | – |
| 7 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -1,519 | $44.09 | – |
| 7 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Sale | -871 | $42.92 | 59,882 |
| 7 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -1,519 | $42.54 | 53,141 |
| 6 Sep 2026 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Retained | +796 | – | 59,882 |
| 6 Sep 2026 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Retained | +1,815 | – | 53,141 |
| 25 Aug 2026 | James Robinson | Independent Director | Derivative Exercise and Retained | +2,000 | – | 8,000 |
| 19 Aug 2026 | Mark Schoenberg | Chief Medical Officer | Open Market Disposition | -60,677 | $47.05 | 59,086 |
| 8 Jul 2026 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $40.00 | 119,763 |
| 21 Jun 2026 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
| 21 Jun 2026 | Stuart Holden | Independent Director | Other Derivative Acquisition | +20,000 | $34.99 | 20,000 |
| 21 Jun 2026 | Arie Belldegrun | Independent Chairperson | Other Derivative Acquisition | +20,000 | $34.99 | 20,000 |
| 21 Jun 2026 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
| 21 Jun 2026 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $35.01 | 129,763 |
| 21 Jun 2026 | James Robinson | Independent Director | Other Derivative Acquisition | +8,000 | – | 8,000 |
| 21 Jun 2026 | James Robinson | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 | 10,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 5,107,819 | 10.4% | 5.1 |
| 15 Oct 2026 | 5,607,261 | 11.5% | 4.9 |
| 30 Sep 2026 | 7,766,918 | 15.9% | 9.9 |
| 15 Sep 2026 | 6,247,498 | 12.8% | 9.2 |
| 31 Aug 2026 | 6,245,387 | 12.8% | 6.8 |
| 14 Aug 2026 | 5,120,407 | 10.5% | 4.8 |
No comments yet — be the first to weigh in on URGN.
Sign in to join the discussion.